<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927377</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300007168</org_study_id>
    <nct_id>NCT04927377</nct_id>
  </id_info>
  <brief_title>Accessible and Inclusive Diabetes Telecoaching Self-Management Program</brief_title>
  <official_title>Accessible and Inclusive Diabetes Telecoaching Self-Management Program: Protocol for a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and pilot test an accessible and inclusive Artificial&#xD;
      Intelligence (AI)-assisted, individualized, family-focused lifestyle modification&#xD;
      intervention (AI4DM) for glycemic control in people with disabilities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AI4DM study will use a two-arm randomized control trial design. Eligible and consented&#xD;
      participants will be assigned to one of two groups: 1) AI4DM intervention group with&#xD;
      telecoaching support, and 2) attention-control group. The active intervention period will&#xD;
      include six months of weekly and bi-weekly telecoaching calls followed by six months of&#xD;
      follow-up and technology access, but no telecoaching calls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The principal investigator and biostatistician will be masked to the randomization of the participants into the two treatment groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Management</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychological distress</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using Diabetes Distress Scale (DDS); Minimum score = 1, maximum score = 6; Higher score represents worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Quality of life</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using the DQoL (Diabetes Quality of Life Measure) Questionnaire; Minimum score =1; maximum score = 5; Higher score represents worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using Diabetes Empowerment Scale; Minimum score = 1; maximum score = 5; Higher score represents better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Family Support</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using the Diabetes Social Support Questionnaire - Family Version (DSSQ-Family); Minimum score = -5 maximum score = 15; Higher score represents better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using Godin leisure-time exercise questionnaire; Minimum score = 0; Maximum score = unknown; Higher score represents better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using The UK Diabetes and Diet Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using the Medication Adherence Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Information Technology</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using The eHealth Literacy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telehealth Dashboard Usability</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using the System Usability Scale; Maximum item score (Strongly agree) = 5, minimum item score (Strongly disagree) = 1; Higher scores represent better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Technology Usability</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measured using the Health Information Usability Evaluation Scale (Health-ITUES)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabete Type 2</condition>
  <condition>Disability Physical</condition>
  <arm_group>
    <arm_group_label>AI4DM Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention-control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>AI4DM</intervention_name>
    <description>Those in the AI4DM intervention arm will receive weekly and bi-weekly calls for six months, access to home and online technology, diabetes-related multimedia educational content, a technology package including a voice-assistive device, wireless glucometer, and wrist-worn activity monitor</description>
    <arm_group_label>AI4DM Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Attention-control</intervention_name>
    <description>Those in the Attention-control Group will receive telecoaching calls at the same frequency of the Intervention Group. Coaching calls will focus on general wellbeing, rather than diabetes-related topics. The Attention-control Group will serve as an untreated comparison group for the Intervention Group.</description>
    <arm_group_label>Attention-control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Type 2 Diabetes Mellitus,&#xD;
&#xD;
          -  Living with a permanent physical disability such as spinal cord injury (SCI), spina&#xD;
             bifida, multiple sclerosis, stroke, etc.&#xD;
&#xD;
          -  Ability to converse and read in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current enrollment in any diabetes-related intervention&#xD;
&#xD;
          -  Severe untreated depression in the past six months&#xD;
&#xD;
          -  Major cardiac event in the past twelve months&#xD;
&#xD;
          -  Uncontrolled blood pressure&#xD;
&#xD;
          -  Resting tachycardia&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Severe peripheral neuropathy&#xD;
&#xD;
          -  Unavailability of a smartphone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric J Evans, PhD</last_name>
    <phone>205-934-7189</phone>
    <email>evansej@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohanraj Thirumalai, PhD</last_name>
    <phone>205-934-7189</phone>
    <email>mohanraj@uab.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Wolff K, Chambers L, Bumol S, White RO, Gregory BP, Davis D, Rothman RL. The PRIDE (Partnership to Improve Diabetes Education) Toolkit: Development and Evaluation of Novel Literacy and Culturally Sensitive Diabetes Education Materials. Diabetes Educ. 2016 Feb;42(1):23-33. doi: 10.1177/0145721715620019. Epub 2015 Dec 7.</citation>
    <PMID>26647414</PMID>
  </reference>
  <reference>
    <citation>Ali MK, Echouffo-Tcheugui J, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Aff (Millwood). 2012 Jan;31(1):67-75. doi: 10.1377/hlthaff.2011.1009. Review.</citation>
    <PMID>22232096</PMID>
  </reference>
  <reference>
    <citation>Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA. 2002 Nov 20;288(19):2469-75.</citation>
    <PMID>12435261</PMID>
  </reference>
  <reference>
    <citation>Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M. Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001 Nov-Dec;4(6):256-62.</citation>
    <PMID>11769298</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Mohanraj Thirumalai</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be submitted to ICPSR.</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

